TY-JUR T1 - DINEZOLID安全，可耐受性和治疗多药和广泛的耐药结核JF - 欧洲呼吸杂志Jo - EUR RESPIR J SP - 730 LP - 733 DO - 10.1183 / 09031936.00195210 VL - 38是 - 3 Au -Villar，M. Au - Sotgiu，G. Au - D'Ambrosio，L. Au - Raymundo，E. Au - Fernandes，L. Au - Barbedo，J.Au - Diogo，N.Au - Lange，C. Au -Centis, R. AU - Migliori, G.B. Y1 - 2011/09/01 UR - //www.qdcxjkg.com/content/38/3/730.abstract N2 - To the Editors:Treatment of multidrug-resistant (MDR) tuberculosis (TB) (defined as in vitro resistance to at least isoniazid and rifampicin, the two most potent first-line drugs for TB treatment) and extensively drug-resistant (XDR)-TB (defined as in vitro resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the injectable drugs: amikacin, capreomycin or kanamycin) is still a major problem from both a clinical and a public health perspective [1–5].Treatment outcomes for complicated MDR-TB cases (those with additional resistance beyond isoniazid and rifampicin) and XDR-TB cases being still poor, the need for information on the safety, tolerability and efficacy of other antibiotics that are potentially useful in their treatment is urgent [6–9].In vitro and pharmacological data suggest that linezolid, an oxazolidinone antibiotic, could be useful in treating mycobacterial infections, including MDR-TB [9–11]. However, clinical experience with the off-label use of linezolid is still limited to case reports and small case series involving nontuberculous mycobacterial diseases [12] and TB, the four largest cohorts including 10 [13], 12 [14], 30 [15] and 85 cases (but only 45 with information on efficacy) [9], respectively. The aim of this study was to evaluate the safety, tolerability and efficacy of linezolid in a cohort of patients with MDR/XDR-TB from Portugal.Clinical information necessary to study safety, tolerability and efficacy was prospectively collected on all MDR-TB cases treated with linezolid in Portugal between 2004 and 2009, with the exception of one case who started the treatment in 2003 (whose information was … ER -